New drug aims to cool inflammation in heart arteries after attack
Disease control
Recruiting now
This study tests a drug called orticumab in 240 people who had a heart attack and still have high inflammation in their heart arteries. Participants receive either orticumab or a placebo for 24 weeks. The main goal is to see if orticumab lowers inflammation measured by a special …
Phase: PHASE2 • Sponsor: Abcentra • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC